Minerva Short Term Debt vs Total Liab Analysis
NERV Stock | USD 2.39 0.12 4.78% |
Minerva Neurosciences financial indicator trend analysis is infinitely more than just investigating Minerva Neurosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Minerva Neurosciences is a good investment. Please check the relationship between Minerva Neurosciences Short Term Debt and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.
Short Term Debt vs Total Liab
Short Term Debt vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Minerva Neurosciences Short Term Debt account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Minerva Neurosciences' Short Term Debt and Total Liab is -0.14. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Liab in the same time period over historical financial statements of Minerva Neurosciences, assuming nothing else is changed. The correlation between historical values of Minerva Neurosciences' Short Term Debt and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Minerva Neurosciences are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Short Term Debt i.e., Minerva Neurosciences' Short Term Debt and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Minerva Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Minerva Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.At this time, Minerva Neurosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to climb to 0.00 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.68) in 2024.
2023 | 2024 (projected) | Extraordinary Items | 8.5M | 7.5M | Reconciled Depreciation | 29.6K | 57.8K |
Minerva Neurosciences fundamental ratios Correlations
Click cells to compare fundamentals
Minerva Neurosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Minerva Neurosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 77.5M | 57.6M | 77.1M | 55.1M | 56.9M | 88.0M | |
Other Current Liab | (41.2B) | 2.1M | 965.7K | 407.9K | 1.5M | 1.6M | |
Total Current Liabilities | 6.6M | 3.2M | 2.8M | 1.4M | 3.3M | 4.4M | |
Total Stockholder Equity | 27.8M | 52.7M | 8.0M | (20.0M) | (28.5M) | (27.0M) | |
Net Debt | (21.1M) | (25.2M) | (60.8M) | 37.6M | 41.0M | 43.1M | |
Retained Earnings | (286.7M) | (284.8M) | (334.7M) | (366.8M) | (396.8M) | (377.0M) | |
Cash | 21.4M | 25.4M | 60.8M | 36.1M | 41.0M | 34.7M | |
Cash And Short Term Investments | 45.9M | 25.4M | 60.8M | 36.1M | 41.0M | 51.4M | |
Common Stock Total Equity | 3.9K | 3.9K | 3.9K | 4.3K | 4.9K | 3.0K | |
Common Stock Shares Outstanding | 4.9M | 5.1M | 5.3M | 5.3M | 6.5M | 4.6M | |
Liabilities And Stockholders Equity | 77.5M | 57.6M | 77.1M | 55.1M | 56.9M | 88.0M | |
Other Current Assets | 1.3B | 2.1B | 1.4B | 4.0M | 989.9K | 940.4K | |
Other Stockholder Equity | 314.5M | 337.5M | 342.7M | 346.8M | 368.4M | 264.5M | |
Total Liab | 49.7M | 5.0M | 69.1M | 75.1M | 85.4M | 42.7M | |
Total Current Assets | 47.1M | 27.4M | 62.2M | 40.2M | 42.0M | 52.9M | |
Common Stock | 3.9K | 4K | 4.3K | 534.0 | 699.0 | 664.05 | |
Property Plant And Equipment Net | 278K | 101.8K | 51.1K | 16.3K | 10.9K | 10.3K | |
Accounts Payable | 2.3M | 995.6K | 1.9M | 969.7K | 1.8M | 1.5M | |
Non Current Assets Total | 30.4M | 30.2M | 14.9M | 14.9M | 14.9M | 27.9M | |
Non Current Liabilities Total | 43.1M | 1.8M | 66.3M | 73.7M | 82.0M | 41.8M | |
Property Plant And Equipment Gross | 278.0K | 101.8K | 0.0 | 16.3K | 18.8K | 17.8K | |
Short Term Debt | 4.0M | (41.2B) | 173K | 111.2K | 100.1K | 105.1K | |
Property Plant Equipment | 33.5K | 16.0K | 101.8K | 16.3K | 18.8K | 36.8K | |
Other Liab | 43.0M | 1.8M | 66.3M | 73.7M | 84.8M | 89.0M | |
Net Tangible Assets | (2.3M) | 22.6M | (6.9M) | (34.9M) | (31.4M) | (29.9M) | |
Retained Earnings Total Equity | (164.4M) | (214.6M) | (286.7M) | (284.8M) | (256.3M) | (269.1M) | |
Capital Surpluse | 296.0M | 304.8M | 314.5M | 337.5M | 388.1M | 278.9M | |
Non Current Liabilities Other | 41.2M | 41.3M | 66.3M | 73.7M | 82.0M | 41.9M | |
Net Invested Capital | 27.8M | 52.7M | 8.0M | (20.0M) | (28.5M) | (27.0M) | |
Net Working Capital | 40.5M | 24.3M | 59.4M | 38.8M | 38.7M | 46.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Minerva Neurosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Minerva Neurosciences' short interest history, or implied volatility extrapolated from Minerva Neurosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Minerva Stock analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Minerva Neurosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Minerva Neurosciences. If investors know Minerva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Minerva Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Return On Assets (0.30) | Return On Equity (6.75) |
The market value of Minerva Neurosciences is measured differently than its book value, which is the value of Minerva that is recorded on the company's balance sheet. Investors also form their own opinion of Minerva Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is Minerva Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Minerva Neurosciences' market value can be influenced by many factors that don't directly affect Minerva Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Minerva Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Minerva Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Minerva Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.